Abstract P3-14-21: Phase II Study of Single Agent Trifunctional Antibody Ertumaxomab (Anti-HER-2 & Anti-CD3) in HER-2 Low Expressing Hormone-Refractory Advanced Breast Cancer Patients (ABC)

2010 ◽  
Author(s):  
F Cardoso ◽  
L Dirix ◽  
PF Conte ◽  
V Semiglazov ◽  
S de Placido ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Single Agent ◽  
Advanced Breast ◽  
Breast Cancer Patients ◽  
Her 2 ◽  
Hormone Refractory

scholarly journals Single-agent oxaliplatin in pretreated advanced breast cancer patients: A phase II study

2001 ◽  
Vol 12 (2) ◽  
pp. 179-182 ◽  
Author(s):  
C. Garufi ◽  
C. Nisticò ◽  
S. Brienza ◽  
A. Vaccaro ◽  
A. D’Ottavio ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Single Agent ◽  
Advanced Breast ◽  
Breast Cancer Patients

Phase II study of divided-dose vinblastine in advanced breast cancer patients

1988 ◽  
Vol 21 (1) ◽  
Author(s):  
Giuseppe Giaccone ◽  
Matteo Bagatella ◽  
Oscar Bertetto ◽  
Michela Donadio ◽  
Alessandro Calciati
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Phase Ii ◽  
Divided Dose ◽  
Phase Ii Study ◽  
Advanced Breast ◽  
Breast Cancer Patients

Paclitaxel and liposomal doxorubicin (Caelyx) combination in advanced breast cancer patients: a Phase II study

2003 ◽  
Author(s):  
Sotiris Rigatos ◽  
Dimitrios Tsavdaridis ◽  
Athanasios Athanasiadis ◽  
John Stathopoulos ◽  
George Stathopoulos
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Phase Ii ◽  
Liposomal Doxorubicin ◽  
Phase Ii Study ◽  
Advanced Breast ◽  
Breast Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document